Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

Micro-Abstract This single-arm phase II trial involving women with recurrent or metastatic breast cancer examined the efficacy and safety of adding bevacizumab to gemcitabine in first-line treatment. The combination was associated with a median progression-free survival (PFS) of 4.8 months, a 1-year...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical breast cancer 2012-10, Vol.12 (5), p.322-330
Hauptverfasser:	Borson, Rachel, Harker, Graydon, Reeves, James, Beck, Thaddeus, Hager, Steven, Horvath, William, Jones, Michael, Tillinghast, Guy, Arrowsmith, Edward, Harrer, Grant, Kudrik, Fred J, Malamud, Stephen C, Bromund, Jane, Zeigler, Haoyue, Tai, Datchen Fritz, Kornberg, Lori J, Obasaju, Coleman, Orlando, Mauro, Yardley, Denise A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - secondary Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological therapy Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Bridged-Ring Compounds - administration & dosage Combination therapy Cytotoxic chemotherapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Female Hematology, Oncology and Palliative Medicine Humans Immunoenzyme Techniques In Situ Hybridization, Fluorescence Locoregionally recurrent Middle Aged Monoclonal antibody Neoadjuvant Therapy Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Staging Obstetrics and Gynecology Prognosis Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Survival Rate Taxoids - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract This single-arm phase II trial involving women with recurrent or metastatic breast cancer examined the efficacy and safety of adding bevacizumab to gemcitabine in first-line treatment. The combination was associated with a median progression-free survival (PFS) of 4.8 months, a 1-year survival rate of 68.7%, and a response rate of 21.4%. There were no unexpected safety signals.
ISSN:	1526-8209 1938-0666
DOI:	10.1016/j.clbc.2012.07.004